JP2001522810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001522810A5 JP2001522810A5 JP2000520146A JP2000520146A JP2001522810A5 JP 2001522810 A5 JP2001522810 A5 JP 2001522810A5 JP 2000520146 A JP2000520146 A JP 2000520146A JP 2000520146 A JP2000520146 A JP 2000520146A JP 2001522810 A5 JP2001522810 A5 JP 2001522810A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- seq
- nucleotides
- iii
- bmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 description 136
- 125000003729 nucleotide group Chemical group 0.000 description 136
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 42
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 42
- 125000003275 alpha amino acid group Chemical group 0.000 description 34
- 229920001184 polypeptide Polymers 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 230000001939 inductive effect Effects 0.000 description 21
- 210000002569 neuron Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 11
- 230000001537 neural effect Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96629797A | 1997-11-07 | 1997-11-07 | |
| US08/966,297 | 1997-11-07 | ||
| PCT/US1998/023827 WO1999024058A2 (en) | 1997-11-07 | 1998-11-06 | Neuronal uses of bmp-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001522810A JP2001522810A (ja) | 2001-11-20 |
| JP2001522810A5 true JP2001522810A5 (enExample) | 2006-06-08 |
Family
ID=25511184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000520146A Pending JP2001522810A (ja) | 1997-11-07 | 1998-11-06 | Ｂｍｐ−１１のニューロンにおける使用 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1028744B1 (enExample) |
| JP (1) | JP2001522810A (enExample) |
| AT (1) | ATE259652T1 (enExample) |
| AU (2) | AU1276399A (enExample) |
| CA (1) | CA2309538A1 (enExample) |
| DE (1) | DE69821793T2 (enExample) |
| DK (1) | DK1028744T3 (enExample) |
| ES (1) | ES2213927T3 (enExample) |
| PT (1) | PT1028744E (enExample) |
| WO (2) | WO1999024057A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030104977A1 (en) * | 2000-03-31 | 2003-06-05 | Ugo Ripamonti | Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US20040259779A1 (en) * | 2001-07-06 | 2004-12-23 | Teit Johansen | Novel neurotrophic factors |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7192717B2 (en) | 2002-02-21 | 2007-03-20 | Wyeth | GASP1: a follistatin domain containing protein |
| CA2476654A1 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| CA2518102C (en) | 2003-03-04 | 2009-05-12 | Tanabe Seiyaku Co., Ltd. | Powdery preparation for nasal administration |
| RU2322261C2 (ru) | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| JP5052517B2 (ja) | 2005-10-06 | 2012-10-17 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| CA2661836A1 (en) | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anti-myostatin antibodies |
| US10092627B2 (en) | 2013-04-08 | 2018-10-09 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating skeletal muscle stem cells |
| US20160220640A1 (en) * | 2013-06-11 | 2016-08-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for increasing neurogenesis and angiogenesis |
| US20160287667A1 (en) * | 2013-11-08 | 2016-10-06 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating neuromuscular junctions |
| EP3949979A1 (en) | 2016-01-06 | 2022-02-09 | President and Fellows of Harvard College | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
| WO2019144053A1 (en) * | 2018-01-19 | 2019-07-25 | President And Fellows Of Harward College | Gdf11 variants and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0698094B1 (en) * | 1993-05-12 | 2004-02-04 | Genetics Institute, LLC | Bmp-11 compositions |
| SE9302550D0 (sv) * | 1993-07-30 | 1993-07-30 | Ernst Hoerlin | Powder inhaler |
| JPH09501932A (ja) * | 1993-08-26 | 1997-02-25 | ジェネティックス・インスティテュート・インコーポレイテッド | ヒト・骨形態形成蛋白を用いる神経再生 |
| US5914234A (en) * | 1994-07-08 | 1999-06-22 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-11 |
-
1998
- 1998-10-23 WO PCT/US1998/022574 patent/WO1999024057A2/en not_active Ceased
- 1998-10-23 AU AU12763/99A patent/AU1276399A/en not_active Withdrawn
- 1998-11-06 JP JP2000520146A patent/JP2001522810A/ja active Pending
- 1998-11-06 CA CA002309538A patent/CA2309538A1/en not_active Abandoned
- 1998-11-06 ES ES98957711T patent/ES2213927T3/es not_active Expired - Lifetime
- 1998-11-06 DE DE69821793T patent/DE69821793T2/de not_active Expired - Lifetime
- 1998-11-06 WO PCT/US1998/023827 patent/WO1999024058A2/en not_active Ceased
- 1998-11-06 AT AT98957711T patent/ATE259652T1/de active
- 1998-11-06 AU AU13900/99A patent/AU761940B2/en not_active Ceased
- 1998-11-06 DK DK98957711T patent/DK1028744T3/da active
- 1998-11-06 EP EP98957711A patent/EP1028744B1/en not_active Expired - Lifetime
- 1998-11-06 PT PT98957711T patent/PT1028744E/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001522810A5 (enExample) | ||
| US9834764B2 (en) | Compositions and methods of using chondroitinase ABCI mutants | |
| JP2004262947A (ja) | 網膜の色素沈着された上皮由来の神経栄養性因子 | |
| AU642947B2 (en) | Non-glycosylated FGF-4 and compositions containing the same | |
| KR970701776A (ko) | 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) | |
| CA2529179A1 (en) | Recombinant adeno-associated virus vector for treatment of alzheimer disease | |
| HU221176B1 (en) | New insulin derivatives with rapid action | |
| CA2338186A1 (en) | Tumor necrosis factor-gamma | |
| HU226168B1 (en) | Analogs of keratinocyte growth factor, nucleic acids coding thereof, process for production and use of the analogs | |
| JP2003527822A5 (enExample) | ||
| JP2002503642A5 (enExample) | ||
| US5858977A (en) | Method of treating diabetes mellitus using KGF | |
| DE3854678T2 (de) | Menschliches Mangansuperoxiddismutase und Behandlungsverfahren. | |
| CA2342770A1 (en) | Ly6h gene | |
| KR920004570A (ko) | 사람 mk 단백질을 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, mk단백질의 생산 방법 및 사용방법 | |
| CN114773428A (zh) | 新多肽及其在制备治疗皮肤创面或黏膜损伤药物中的应用 | |
| WO1996031607A3 (en) | Use of an 'immunodeficiency-virus suppressing lymphokine (isl)' to inhibit the replication of viruses, in particular of retroviruses | |
| CA2220854A1 (en) | Anti-ulcer composition | |
| WO1997005893A1 (en) | Remedy for ophthalmic diseases | |
| CA2356009A1 (en) | Vascular endothelial growth factor-x | |
| Laguda et al. | Assignment of the Hepatocyte Growth Factor (HGF) to chromosome 7q22‐qter | |
| JP3744026B2 (ja) | 眼科疾患治療剤 | |
| Oliveira et al. | Site-directed mutagenesis of bovine FGF-2 cDNA allows the production of the human-form of FGF-2 in Escherichia coli | |
| US6903188B2 (en) | Neurogenic compositions and methods | |
| JPH0725798B2 (ja) | ＴＧＦ−β制御糖タンパク質 |